AcelleRX Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
AcelleRX Therapeutics aims to help people who suffer a myocardial infarction (MI) or chronic heart failure (HF) via a gene or protein capable of recruiting stem cells to help repair the heart. If the science can be successfully commercialized, this spin-out from the Cleveland Clinic in Ohio could have a big impact on a big slice of the market.
You may also be interested in...
Cardiovascular Drug Start-Ups
The cardiovascular drug marketplace has the dubious distinction of being the largest therapeutic category in terms of revenue, unmet need and mortality, while at the same time being the only area experiencing decreasing growth. Revenues will start to plummet starting in 2012 when the world's two largest CV drugs--Lipitor and Plavix--go generic. To help pharmas replace these and other aging drugs in their pipelines, Windhover's Therapeutic Alliances conference presents the "top 10" unpartnered clinical-stage cardiovascular programs.
Start-Up Previews (10/2007)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Cardiovascular Drug Start-Ups," features profiles of AcelleRX Therapeutics, BioVascular, Nile Therapeutics and VIA Pharmaceuticals. Plus these Start-Ups Across Health Care: JenaValve, Moberg Derma, ProtAffin, and Virtual Ports.
Cardiovascular Drug Start-Ups
The cardiovascular drug marketplace has the dubious distinction of being the largest therapeutic category in terms of revenue, unmet need and mortality, while at the same time being the only area experiencing decreasing growth. Revenues will start to plummet starting in 2012 when the world's two largest CV drugs--Lipitor and Plavix--go generic. To help pharmas replace these and other aging drugs in their pipelines, Windhover's Therapeutic Alliances conference presents the "top 10" unpartnered clinical-stage cardiovascular programs.